NYSE:AGNAllergan Stock Price, Forecast & News

$193.02

+0.03 (+0.02 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$191.64

Now: $193.02▼

$193.38

50-Day Range

$175.71

MA: $188.04▼

$193.89

52-Week Range

$114.27

Now: $193.02▼

$202.21

Volume12.44 million shs

Average Volume4.01 million shs

Market Capitalization$63.50 billion

P/E RatioN/A

Dividend Yield1.53%

Beta1.2

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Allergan has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 12 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $186.71, Allergan has a potential downside of 3.3% from its current price of $193.02.
Amount of Analyst Coverage
Allergan has only been the subject of 2 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Allergan has received 1,382 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Allergan has received 697 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Allergan has received 66.47% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote “Outperform” if you believe AGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Allergan is a leading dividend payer. It pays a dividend yield of 1.53%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Allergan has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of Allergan is 16.78 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Allergan will have a dividend payout ratio of 16.33 % next year. This indicates that Allergan will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allergan insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.08% of the stock of Allergan is held by insiders.
Percentage Held by Institutions
83.91% of the stock of Allergan is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Allergan are expected to grow by 8.56% in the coming year, from $16.70 to $18.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allergan is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allergan is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Allergan has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Allergan has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:AGN

Previous SymbolNYSE:ACT

CUSIP01849010

CIK1578845

Webwww.allergan.com

Phone862-261-7000

Debt

Debt-to-Equity Ratio0.31

Current Ratio1.01

Quick Ratio0.84

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio11.56

P/E Growth1.63

Sales & Book Value

Annual Sales$16.09 billion

Price / Sales3.95

Cash Flow$36.70 per share

Price / Cash Flow5.26

Book Value$177.28 per share

Price / Book1.09

Profitability

EPS (Most Recent Fiscal Year)$17.64

Net Income$-5,271,000,000.00

Net Margins-15.44%

Return on Equity8.46%

Return on Assets5.31%

Miscellaneous

Employees17,400

Outstanding Shares329,002,000

Market Cap$63.50 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Allergan (NYSE:AGN) Frequently Asked Questions

How has Allergan's stock been impacted by COVID-19 (Coronavirus)?

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have increased by 4.1% and is now trading at $193.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allergan?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

When is Allergan's next earnings date?

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping analysts' consensus estimates of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.29 earnings per share. View Allergan's earnings history.

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be paid a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, April 15th. View Allergan's dividend history.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

What price target have analysts set for AGN?

13 equities research analysts have issued 12-month price objectives for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they anticipate Allergan's stock price to reach $186.71 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Allergan.

Has Allergan been receiving favorable news coverage?

Media headlines about AGN stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a news impact score of -4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days. View the latest news aboutAllergan.

Who are some of Allergan's key competitors?

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the following people:

Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Who are Allergan's major shareholders?

Allergan's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.42%), State Street Corp (4.15%), Longview Partners Guernsey LTD (1.52%), Clearbridge Investments LLC (1.24%), JPMorgan Chase & Co. (1.12%) and Morgan Stanley (0.84%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh. View institutional ownership trends for Allergan.

Which major investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Nuveen Asset Management LLC, Clearbridge Investments LLC, State Street Corp, Segantii Capital Management Ltd, Scharf Investments LLC, Canyon Capital Advisors LLC, and Mackenzie Financial Corp. View insider buying and selling activity for Allergan.

Which major investors are buying Allergan stock?

AGN stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., ING Groep NV, BlackRock Inc., Water Island Capital LLC, Maso Capital Partners Ltd, Glazer Capital LLC, and Swiss National Bank. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How big of a company is Allergan?

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

What is Allergan's official website?

The official website for Allergan is www.allergan.com.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff